Exagen (NASDAQ:XGN) Now Covered by Analysts at B. Riley

B. Riley started coverage on shares of Exagen (NASDAQ:XGN) in a research report report published on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $15.00 target price on the stock.

A number of other equities analysts have also weighed in on the stock. Craig Hallum initiated coverage on shares of Exagen in a research report on Wednesday, July 23rd. They set a “buy” rating and a $12.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price on shares of Exagen in a research report on Wednesday, July 30th. UBS Group restated an “overweight” rating on shares of Exagen in a research report on Thursday, May 15th. KeyCorp raised shares of Exagen from a “sector weight” rating to an “overweight” rating and set a $12.00 target price on the stock in a report on Wednesday, July 30th. Finally, Canaccord Genuity Group raised their price target on shares of Exagen from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, July 30th. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $12.00.

Exagen Price Performance

Shares of NASDAQ:XGN opened at $10.00 on Thursday. The company has a quick ratio of 4.95, a current ratio of 4.95 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $220 million, a PE ratio of -11.24 and a beta of 1.60. Exagen has a twelve month low of $2.38 and a twelve month high of $10.34. The company has a 50-day moving average price of $8.64 and a two-hundred day moving average price of $6.52.

Exagen (NASDAQ:XGN) last issued its earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. Exagen has set its FY 2025 guidance at EPS. Equities analysts forecast that Exagen will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Exagen

Several hedge funds have recently bought and sold shares of XGN. Toronto Dominion Bank bought a new stake in Exagen during the fourth quarter valued at approximately $3,655,000. Balyasny Asset Management L.P. bought a new stake in Exagen during the second quarter valued at approximately $5,017,000. Russell Investments Group Ltd. bought a new stake in Exagen during the second quarter valued at approximately $1,540,000. FourWorld Capital Management LLC bought a new stake in Exagen during the second quarter valued at approximately $1,456,000. Finally, Manatuck Hill Partners LLC bought a new stake in Exagen during the second quarter valued at approximately $1,222,000. 75.25% of the stock is currently owned by institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).